Thank you, Madam Chair.
I do want to go again from the top.
I want to spend some time on this new motion that was moved by Dan Mazier.
I think paragraph i) of the motion carries more weight than it might initially appear to. The more closely I see that, the more concern I have.
I just want to be clear on this. Our government supports transparency, Madam Chair. That has been consistent, that it guides the work of Health Canada and organizations like Canada Health Infoway.
Transparency needs to be approached carefully. It must be balanced with the privacy consideration, the legal responsibilities and the integrity of the systems Canadians depend on every day. In my view, the motion does not have that balance.
I'll start with paragraph i) on PrescribeIT. PrescribeIT is an initiative that we should recognize as progress. It is a national e-prescribing service that improves communication between doctors and pharmacists, reduces errors and strengthens patient safety. It is part of a broader effort to modernize Canada's health care system.
However, the scope of what's being requested here goes well beyond typical oversight. It includes contracts, amendments and renewals dating back to 2017; intellectual property agreements; termination details; payment records and even internal advice to the minister's office.
This is not a narrow or targeted request. It is very extensive. We need to consider what fulfilling a request of this magnitude would entail. There are clear issues around commercial sensitivity, especially with partners like Telus Health. These agreements often include property.... Releasing that information without proper safeguards could compromise future negotiations and partnership.
There are also security considerations. We are talking about digital health infrastructure systems that Canadians rely on. Making detailed internal information about these systems public could create vulnerabilities. Another major concern is the inclusion of internal recommendation documents. Public servants need to be able to provide candid, unfiltered advice that depends on a level of confidentiality. If that is removed, it risks affecting how decisions are made, and not in a positive way.
With regard to the agreement between Canadian Blood Services and Grifols, it is important to remember that Canadian Blood Services operates independently. It is a not-for-profit organization working with the provinces and territories to manage Canada's blood and plasma supply. This system is essential. It supports patients across the country who depend on plasma and plasma-derived therapies for serious and often lifelong conditions. These partnerships, including those with companies like Grifols, are key to maintaining a stable and reliable supply.
A request for all agreements and related documents raises legitimate concerns. These agreements can involve sensitive commercial information and international supply chains. In some cases, they may not fall entirely within the federal jurisdiction, so we must be cautious not to undermine confidence in a system that Canadians trust to be managed safely and professionally.
Finally, paragraph k) deals with data shared with Health Canada in urgent public health contexts, including all the...managed safely and professionally. We all recognize the severity of that crisis. The data referenced here goes beyond summary reports and includes underlying datasets. That also raises serious concerns about patient privacy, data protection and how that information is handled. It also touches on—